胰高血糖素样肽-1受体激动剂概述

Overview of Glucagon-like Peptide-1 Receptor Agonists.

作者信息

Steadman Laura, Grant Joan S, Graven Lucinda J

机构信息

Laura Steadman, EdD, CRNP, is an Assistant Professor, School of Nursing, University of Alabama at Birmingham, Birmingham, Alabama. Joan S. Grant, PhD, RN, is a Professor, School of Nursing, University of Alabama at Birmingham, Birmingham, Alabama. Lucinda J. Graven, PhD, MSN, ARNP, is an Assistant Professor, College of Nursing, Florida State University, Tallahassee, Florida.

出版信息

Home Healthc Now. 2015 Nov-Dec;33(10):538-44. doi: 10.1097/NHH.0000000000000312.

DOI:10.1097/NHH.0000000000000312

PMID:26529445

Abstract

Type 2 diabetes mellitus is an increasingly prevalent disease in the United States and globally. Multiple pharmacologic therapies are typically required over time to achieve and maintain target blood glucose levels. When first-line oral medications such as metformin (Glucophage) are not effective in achieving desired glycosylated hemoglobin (HbA1C) levels, glucagon-like peptide-1 receptor agonists may be used. This article provides an overview of this class of agents and provides implications for home healthcare clinicians.

摘要

2型糖尿病在美国乃至全球都是一种日益普遍的疾病。随着时间的推移，通常需要多种药物治疗来达到并维持目标血糖水平。当一线口服药物如二甲双胍（格华止）无法有效达到理想的糖化血红蛋白（HbA1C）水平时，可使用胰高血糖素样肽-1受体激动剂。本文概述了这类药物，并为家庭医疗保健临床医生提供相关启示。